AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 8267129 — intervention group
Group type: COMPARATOR
Intervention: Haloperidol
Number of subjects: 39
Study 2447995 — intervention group
Group type: EXPERIMENTAL
Intervention: Indoramin
Number of subjects: 30
Study 2447995 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30
Study 31385847 — intervention group
Group type: EXPERIMENTAL
Intervention: Participants who were male, white, low-income, college graduates, and younger
Number of subjects: 2605
Study 31385847 — intervention group
Group type: EXPERIMENTAL
Intervention: Information given about initiation of opioid use (received prescription opioids from a doctor)
Number of subjects: 2605
Study 31385847 — intervention group
Group type: EXPERIMENTAL
Intervention: Information given about initiation of opioid use (took prescription opioids from a friend)
Number of subjects: 2605
Study 29958916 — intervention group
Group type: EXPERIMENTAL
Intervention: sfCOMP-Bio
Number of subjects: 121
Study 29958916 — intervention group
Group type: COMPARATOR
Intervention: sCOMP-Bio
Number of subjects: 121
Study 29958916 — intervention group
Group type: COMPARATOR
Intervention: sCOMP-Ana
Number of subjects: 121
Study 27028445 — intervention group
Group type: EXPERIMENTAL
Intervention: Warfarin plus low-dose aspirin (75 mg)
Number of subjects: 316
Study 27028445 — intervention group
Group type: COMPARATOR
Intervention: Warfarin alone
Number of subjects: 316
Study 25698450 — intervention group
Group type: EXPERIMENTAL
Intervention: Gefitinib
Number of subjects: 127
Study 25698450 — intervention group
Group type: EXPERIMENTAL
Intervention: Gemcitabine
Number of subjects: 127
Study 25698450 — intervention group
Group type: EXPERIMENTAL
Intervention: Docetaxel
Number of subjects: 127
Study 25698450 — intervention group
Group type: COMPARATOR
Intervention: Control (younger patients)
Number of subjects: 127
Study 25698450 — intervention group
Group type: COMPARATOR
Intervention: Control (elderly patients)
Number of subjects: 127
Study 25698450 — intervention group
Group type: EXPERIMENTAL
Intervention: Single-agent chemotherapy
Number of subjects: 127
Study 25698450 — intervention group
Group type: EXPERIMENTAL
Intervention: Age as a prognostic factor
Number of subjects: 127
Study 24223736 — intervention group
Group type: EXPERIMENTAL
Intervention: Hydrophobic acrylic IOLs
Number of subjects: 861
Study 24223736 — intervention group
Group type: COMPARATOR
Intervention: Hydrophilic acrylic IOLs
Number of subjects: 861
Study 21138720 — intervention group
Group type: EXPERIMENTAL
Intervention: Naltrexone (Revia)
Number of subjects: 603
Study 21138720 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 603
Study 19756236 — intervention group
Group type: EXPERIMENTAL
Intervention: Ultrabrief right unilateral ECT
Number of subjects: 90
Study 19756236 — intervention group
Group type: COMPARATOR
Intervention: Ultrabrief bilateral ECT
Number of subjects: 90
Study 19756236 — intervention group
Group type: COMPARATOR
Intervention: Standard pulse width bilateral ECT
Number of subjects: 90
Study 19756236 — intervention group
Group type: COMPARATOR
Intervention: Standard pulse width unilateral ECT
Number of subjects: 90
Study 16899965 — intervention group
Group type: EXPERIMENTAL
Intervention: Intermittent alternating right-left stimulation
Number of subjects: 21
Study 16899965 — intervention group
Group type: EXPERIMENTAL
Intervention: Intermittent simultaneous bilateral stimulation
Number of subjects: 21
Study 16899965 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous bilateral stimulation
Number of subjects: 21
Study 12814449 — intervention group
Group type: EXPERIMENTAL
Intervention: Netilmicin (100 mg) administered as a maximum of four successive intravenous infusions of 30 min, at 8-h intervals.
Number of subjects: 62
Study 12814449 — intervention group
Group type: EXPERIMENTAL
Intervention: Population covariate model based on sex and creatinine clearance.
Number of subjects: 62
Study 11082221 — intervention group
Group type: EXPERIMENTAL
Intervention: Adjuvant polychemotherapy with FAM (5‐fluorouracil, Adriamycin, and mitomycin C)
Number of subjects: 53
Study 11082221 — intervention group
Group type: COMPARATOR
Intervention: Control group (28 patients who had only undergone radical resection)
Number of subjects: 53
Study 8867250 — intervention group
Group type: EXPERIMENTAL
Intervention: EMLA
Number of subjects: 258
Study 8867250 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 258
Study 1644095 — intervention group
Group type: EXPERIMENTAL
Intervention: Aggressive lipid-altering therapy
Number of subjects: 0
Study 6376265 — intervention group
Group type: EXPERIMENTAL
Intervention: Hepatitis B immune globulin
Number of subjects: 34
Study 6376265 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 34
Study 30916898 — intervention group
Group type: EXPERIMENTAL
Intervention: Copolymer-1 (Cop-1)
Number of subjects: 38
Study 30916898 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 38
Study 30382923 — intervention group
Group type: EXPERIMENTAL
Intervention: Electrically guided implantation of the LV lead using electrical mapping towards the latest LV activation.
Number of subjects: 122
Study 30382923 — intervention group
Group type: COMPARATOR
Intervention: Imaging-guided implantation of the LV lead using echocardiography and myocardial perfusion imaging.
Number of subjects: 122
Study 30382923 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups (intervention and control)
Number of subjects: 122
Study 25345540 — intervention group
Group type: EXPERIMENTAL
Intervention: Long-chain omega-3 polyunsaturated fatty acids (PUFAs)
Number of subjects: 80
Study 25345540 — intervention group
Group type: COMPARATOR
Intervention: Paraffin oil (placebo)
Number of subjects: 80
Study 24338799 — intervention group
Group type: EXPERIMENTAL
Intervention: Dyadic exercise regimen (individually tailored walking regimen designed to become progressively intensive, lasting between 20-30 minutes, at least five times per week)
Number of subjects: 131
Study 24338799 — intervention group
Group type: COMPARATOR
Intervention: Control group (no exercise regimen)
Number of subjects: 131
Study 24338799 — intervention group
Group type: EXPERIMENTAL
Intervention: Dyadic exercise regimen
Number of subjects: 131
Study 23270333 — intervention group
Group type: EXPERIMENTAL
Intervention: LI10903F (300 mg thrice daily)
Number of subjects: 50
Study 23270333 — intervention group
Group type: COMPARATOR
Intervention: Placebo (300 mg thrice daily)
Number of subjects: 50
Study 20702111 — intervention group
Group type: EXPERIMENTAL
Intervention: Knee joint cryotherapy application (20 min with a crushed-ice bag)
Number of subjects: 20
Study 20702111 — intervention group
Group type: COMPARATOR
Intervention: Control group (rest for 20 min)
Number of subjects: 20
Study 18399341 — intervention group
Group type: EXPERIMENTAL
Intervention: Unilateral spinal anaesthesia (10 mg of 0.5% hyperbaric bupivacaine)
Number of subjects: 74
Study 18399341 — intervention group
Group type: COMPARATOR
Intervention: Conventional spinal anaesthesia (10 mg of 0.5% hyperbaric bupivacaine)
Number of subjects: 74
Study 18399341 — intervention group
Group type: COMPARATOR
Intervention: Conventional spinal anaesthesia
Number of subjects: 74
Study 18399341 — intervention group
Group type: EXPERIMENTAL
Intervention: Unilateral spinal anaesthesia
Number of subjects: 74
Study 15276098 — intervention group
Group type: EXPERIMENTAL
Intervention: Irbesartan treatment
Number of subjects: 1387
Study 11557651 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin E 500 IU/day
Number of subjects: 77
Study 11557651 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 77
Study 9566367 — intervention group
Group type: EXPERIMENTAL
Intervention: tPA treatment
Number of subjects: 1000
Study 7995835 — intervention group
Group type: EXPERIMENTAL
Intervention: Endothelial cell seeded graft limb
Number of subjects: 15
Study 7995835 — intervention group
Group type: COMPARATOR
Intervention: Non-seeded graft limb (Control)
Number of subjects: 15
Study 2739680 — intervention group
Group type: EXPERIMENTAL
Intervention: Test cigarette (tobacco-heating); smokers
Number of subjects: 72
Study 2739680 — intervention group
Group type: COMPARATOR
Intervention: Reference cigarette (tobacco-burning); smokers
Number of subjects: 72
Study 2739680 — intervention group
Group type: COMPARATOR
Intervention: Non-smokers
Number of subjects: 72
Study 31816425 — intervention group
Group type: EXPERIMENTAL
Intervention: Chair elastic-band muscle strength exercises (CSE), n = 20, 45 min, 3 times/week for 28 weeks
Number of subjects: 60
Study 31816425 — intervention group
Group type: EXPERIMENTAL
Intervention: Chair-multimodal exercise (CME), n = 21, 45 min, 3 times/week for 28 weeks
Number of subjects: 60
Study 31816425 — intervention group
Group type: COMPARATOR
Intervention: Control non-exercise group (CGne), n = 19
Number of subjects: 60
Study 31542128 — intervention group
Group type: EXPERIMENTAL
Intervention: Mobile app providing educational resources, goal setting, self-monitoring, and feedback strategies for 12 weeks
Number of subjects: 160
Study 28719039 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral steroid therapy
Number of subjects: 111
Study 28719039 — intervention group
Group type: EXPERIMENTAL
Intervention: Intratympanic dexamethasone injection (IT)
Number of subjects: 111
Study 28719039 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination therapy
Number of subjects: 111
Study 28719039 — intervention group
Group type: COMPARATOR
Intervention: Low-frequency group
Number of subjects: 111
Study 28719039 — intervention group
Group type: COMPARATOR
Intervention: High-frequency group
Number of subjects: 111
Study 25101909 — intervention group
Group type: COMPARATOR
Intervention: Conventional brackets (group 1, n = 20)
Number of subjects: 60
Study 25101909 — intervention group
Group type: COMPARATOR
Intervention: Self-ligating brackets (group 2, n = 20)
Number of subjects: 60
Study 25101909 — intervention group
Group type: COMPARATOR
Intervention: Control group (group 3, n = 20)
Number of subjects: 60
Study 25101909 — intervention group
Group type: EXPERIMENTAL
Intervention: All groups (including control)
Number of subjects: 60
Study 23811639 — intervention group
Group type: EXPERIMENTAL
Intervention: Preflared group (initial instrumentation with preflaring)
Number of subjects: 90
Study 23811639 — intervention group
Group type: COMPARATOR
Intervention: Nonpreflared group (initial instrumentation without preflaring)
Number of subjects: 90
Study 21232112 — intervention group
Group type: EXPERIMENTAL
Intervention: Land-based exercise group
Number of subjects: 618
Study 21232112 — intervention group
Group type: EXPERIMENTAL
Intervention: Water-based exercise group
Number of subjects: 618
Study 21232112 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 618
Study 19900236 — intervention group
Group type: EXPERIMENTAL
Intervention: Pioglitazone (force-titrated to 45 mg/day, n = 654)
Number of subjects: 1314
Study 19900236 — intervention group
Group type: COMPARATOR
Intervention: Placebo (n = 660)
Number of subjects: 1314
Study 15758560 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral glucose (100 g) administered at -30 min followed by TRH (200 microg iv) at 0 min
Number of subjects: 7
Study 15758560 — intervention group
Group type: EXPERIMENTAL
Intervention: Isoproterenol (0.012 microg/kg, iv) infused continuously with TRH (200 microg iv) at 0 min
Number of subjects: 7
Study 15758560 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral glucose (100 g) at -30 min and isoproterenol infused continuously with TRH (200 microg iv) at 0 min
Number of subjects: 7
Study 15758560 — intervention group
Group type: COMPARATOR
Intervention: TRH (200 microg iv) at 0 min without glucose or isoproterenol
Number of subjects: 7
Study 12192476 — intervention group
Group type: EXPERIMENTAL
Intervention: Collection of fetal blood before delivery of the placenta
Number of subjects: 0
Study 12192476 — intervention group
Group type: COMPARATOR
Intervention: Collection of fetal blood after delivery of the placenta
Number of subjects: 0
Study 9794346 — intervention group
Group type: EXPERIMENTAL
Intervention: 25 mg carvedilol twice daily
Number of subjects: 122
Study 9794346 — intervention group
Group type: EXPERIMENTAL
Intervention: 50 mg carvedilol twice daily
Number of subjects: 122
Study 9794346 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 122
Study 9794346 — intervention group
Group type: EXPERIMENTAL
Intervention: 12.5 mg carvedilol twice daily
Number of subjects: 122
Study 7613927 — intervention group
Group type: EXPERIMENTAL
Intervention: J colonic pouch-anal anastomosis
Number of subjects: 40
Study 7613927 — intervention group
Group type: COMPARATOR
Intervention: Straight coloanal anastomosis
Number of subjects: 40
Study 1978474 — intervention group
Group type: EXPERIMENTAL
Intervention: Remoxipride (150-600 mg daily for 6 weeks)
Number of subjects: 98
Study 1978474 — intervention group
Group type: COMPARATOR
Intervention: Haloperidol (5-20 mg daily for 6 weeks)
Number of subjects: 98
Study 735716 — intervention group
Group type: EXPERIMENTAL
Intervention: Cimetidine
Number of subjects: 0
Study 30627833 — intervention group
Group type: COMPARATOR
Intervention: Unsupported worked examples
Number of subjects: 3
Study 30627833 — intervention group
Group type: EXPERIMENTAL
Intervention: Closed prompts (multiple-choice tasks)
Number of subjects: 3
Study 30627833 — intervention group
Group type: EXPERIMENTAL
Intervention: Open reflection prompts
Number of subjects: 3
Study 28497943 — intervention group
Group type: EXPERIMENTAL
Intervention: OTC self-adapted jaw-repositioning mouthguard (SA)
Number of subjects: 20
Study 28497943 — intervention group
Group type: EXPERIMENTAL
Intervention: OTC custom-fitted jaw-repositioning mouthguard (CF)
Number of subjects: 20
Study 28497943 — intervention group
Group type: EXPERIMENTAL
Intervention: Placebo mouthguard (PLA)
Number of subjects: 20
Study 28497943 — intervention group
Group type: COMPARATOR
Intervention: No mouthguard control (CON)
Number of subjects: 20
Study 28497943 — intervention group
Group type: EXPERIMENTAL
Intervention: All conditions (CON, PLA, SA, CF)
Number of subjects: 20
Study 24819823 — intervention group
Group type: EXPERIMENTAL
Intervention: Histamine
Number of subjects: 30
Study 24819823 — intervention group
Group type: EXPERIMENTAL
Intervention: Capsaicin
Number of subjects: 30
Study 24819823 — intervention group
Group type: EXPERIMENTAL
Intervention: Cowhage
Number of subjects: 30
Study 24819823 — intervention group
Group type: EXPERIMENTAL
Intervention: Female subjects
Number of subjects: 30
Study 24819823 — intervention group
Group type: EXPERIMENTAL
Intervention: Male subjects
Number of subjects: 30
Study 23921778 — intervention group
Group type: EXPERIMENTAL
Intervention: Primary care-based weight loss intervention
Number of subjects: 0
Study 19282347 — intervention group
Group type: EXPERIMENTAL
Intervention: Linear treadmill protocol
Number of subjects: 16
Study 19282347 — intervention group
Group type: EXPERIMENTAL
Intervention: Bruce protocol
Number of subjects: 16
Study 19282347 — intervention group
Group type: COMPARATOR
Intervention: Cycle ergometry
Number of subjects: 16
Study 17333340 — intervention group
Group type: EXPERIMENTAL
Intervention: Letrozole 2.5 mg
Number of subjects: 907
Study 17333340 — intervention group
Group type: COMPARATOR
Intervention: Tamoxifen 20 mg
Number of subjects: 907
Study 15155391 — intervention group
Group type: COMPARATOR
Intervention: Diet eliminating artificial colourings and benzoate preservatives for one week followed by a three week double blind crossover study with a drink containing artificial colourings (20 mg daily) and sodium benzoate (45 mg daily) during active periods.
Number of subjects: 277
Study 15155391 — intervention group
Group type: COMPARATOR
Intervention: Placebo mixture during the placebo period.
Number of subjects: 277
Study 11549686 — intervention group
Group type: EXPERIMENTAL
Intervention: Growth hormone (GH) 0.3 mg/kg/week
Number of subjects: 19
Study 11549686 — intervention group
Group type: COMPARATOR
Intervention: Control group (no GH)
Number of subjects: 19
Study 11549686 — intervention group
Group type: EXPERIMENTAL
Intervention: Cystic fibrosis subgroup
Number of subjects: 19
Study 11549686 — intervention group
Group type: EXPERIMENTAL
Intervention: Cystic fibrosis subgroups
Number of subjects: 19
Study 9039927 — intervention group
Group type: EXPERIMENTAL
Intervention: CsA alone (group 1)
Number of subjects: 53
Study 9039927 — intervention group
Group type: EXPERIMENTAL
Intervention: CsA plus steroids (group 2)
Number of subjects: 53
Study 9039927 — intervention group
Group type: EXPERIMENTAL
Intervention: CsA plus steroids plus azathioprine (group 3)
Number of subjects: 53
Study 7895587 — intervention group
Group type: EXPERIMENTAL
Intervention: rhGM‐CSF (leucomax) with chemotherapy
Number of subjects: 21
Study 7895587 — intervention group
Group type: COMPARATOR
Intervention: Control group (only chemotherapy)
Number of subjects: 21
Study 7895587 — intervention group
Group type: EXPERIMENTAL
Intervention: rhGM‐CSF (leucomax)
Number of subjects: 21
Study 3285117 — intervention group
Group type: EXPERIMENTAL
Intervention: 60 or 85 g fructose
Number of subjects: 12
Study 3285117 — intervention group
Group type: COMPARATOR
Intervention: Sweet placebo
Number of subjects: 12
Study 29884082 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral paracetamol premedication
Number of subjects: 240
Study 29884082 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 240
Study 26965503 — intervention group
Group type: EXPERIMENTAL
Intervention: 80-kV protocol A (PA; 0.75 g iodine/kg)
Number of subjects: 30
Study 26965503 — intervention group
Group type: EXPERIMENTAL
Intervention: 80-kV protocol B (PB; 1 g iodine/kg)
Number of subjects: 30
Study 26965503 — intervention group
Group type: COMPARATOR
Intervention: 120-kV standard protocol (PS; 0.75 g iodine/kg)
Number of subjects: 30
Study 23873632 — intervention group
Group type: EXPERIMENTAL
Intervention: Denosumab (DMAb)
Number of subjects: 2363
Study 23873632 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 2363
Study 23981616 — intervention group
Group type: EXPERIMENTAL
Intervention: Intracoronary bolus of tirofiban (10 µg/kg)
Number of subjects: 490
Study 23981616 — intervention group
Group type: COMPARATOR
Intervention: Intracoronary bolus of urokinase (250 kU/20 ml)
Number of subjects: 490
Study 23981616 — intervention group
Group type: EXPERIMENTAL
Intervention: Intracoronary bolus of tirofiban
Number of subjects: 490
Study 20836720 — intervention group
Group type: EXPERIMENTAL
Intervention: Transvesical obturator nerve block (ONB) with spinal anesthesia
Number of subjects: 60
Study 20836720 — intervention group
Group type: COMPARATOR
Intervention: Spinal anesthesia only (Control)
Number of subjects: 60
Study 17960366 — intervention group
Group type: EXPERIMENTAL
Intervention: Nicotinized cigarette (NIC+)
Number of subjects: 165
Study 17960366 — intervention group
Group type: COMPARATOR
Intervention: Denicotinized cigarette (NIC‐)
Number of subjects: 165
Study 15842075 — intervention group
Group type: EXPERIMENTAL
Intervention: Listening to Vivaldi's Four Seasons
Number of subjects: 0
Study 15842075 — intervention group
Group type: COMPARATOR
Intervention: No music
Number of subjects: 0
Study 12005359 — intervention group
Group type: EXPERIMENTAL
Intervention: Fiduxosin 30 mg
Number of subjects: 48
Study 12005359 — intervention group
Group type: EXPERIMENTAL
Intervention: Fiduxosin 60 mg
Number of subjects: 48
Study 12005359 — intervention group
Group type: EXPERIMENTAL
Intervention: Fiduxosin 90 mg
Number of subjects: 48
Study 12005359 — intervention group
Group type: EXPERIMENTAL
Intervention: Fiduxosin 120 mg
Number of subjects: 48
Study 12005359 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 48
Study 10065062 — intervention group
Group type: COMPARATOR
Intervention: Written materials only
Number of subjects: 191
Study 10065062 — intervention group
Group type: COMPARATOR
Intervention: Written materials and videotape
Number of subjects: 191
Study 10065062 — intervention group
Group type: EXPERIMENTAL
Intervention: Written materials and small-group sessions facilitated by fourth-year medical students
Number of subjects: 191
Study 10065062 — intervention group
Group type: COMPARATOR
Intervention: All three methods
Number of subjects: 191
Study 7751411 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous flucloxacillin (500 mg)
Number of subjects: 7
Study 7751411 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral flucloxacillin (500 mg)
Number of subjects: 7
Study 7751411 — intervention group
Group type: COMPARATOR
Intervention: Comparison with young healthy subjects
Number of subjects: 7
Study 7751411 — intervention group
Group type: EXPERIMENTAL
Intervention: Flucloxacillin renal clearance (Clr) regression on estimated creatine clearance (CLcr)
Number of subjects: 7
Study 7751411 — intervention group
Group type: EXPERIMENTAL
Intervention: Total clearance, renal clearance, and volume of distribution
Number of subjects: 7
Study 2268141 — intervention group
Group type: EXPERIMENTAL
Intervention: Insulin (0.1 U/kg)
Number of subjects: 15
Study 2268141 — intervention group
Group type: COMPARATOR
Intervention: Saline administration
Number of subjects: 15
Study 263132 — intervention group
Group type: EXPERIMENTAL
Intervention: Barium enema studies
Number of subjects: 73
Study 30669509 — intervention group
Group type: EXPERIMENTAL
Intervention: Psyllium
Number of subjects: 24
Study 30669509 — intervention group
Group type: COMPARATOR
Intervention: Placebo (maltodextrin)
Number of subjects: 24
Study 29252175 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical capsaicin solution
Number of subjects: 27
Study 29252175 — intervention group
Group type: COMPARATOR
Intervention: Immersion oil (Control group)
Number of subjects: 27
Study 25675380 — intervention group
Group type: EXPERIMENTAL
Intervention: Metformin (850 mg bid) for 6 months
Number of subjects: 178
Study 25675380 — intervention group
Group type: COMPARATOR
Intervention: Control group (healthy women)
Number of subjects: 178
Study 23307540 — intervention group
Group type: EXPERIMENTAL
Intervention: Pharmacy case manager recommendations accepted by inpatient physicians
Number of subjects: 192
Study 23307540 — intervention group
Group type: EXPERIMENTAL
Intervention: Recommendations related to updating the record after medication reconciliation
Number of subjects: 192
Study 23307540 — intervention group
Group type: EXPERIMENTAL
Intervention: Recommendations related to actual allergies
Number of subjects: 192
Study 23307540 — intervention group
Group type: EXPERIMENTAL
Intervention: Recommendations related to medication errors
Number of subjects: 192
Study 23307540 — intervention group
Group type: EXPERIMENTAL
Intervention: Recommendations related to drug indications
Number of subjects: 192
Study 23307540 — intervention group
Group type: EXPERIMENTAL
Intervention: Recommendations related to drug efficacy
Number of subjects: 192
Study 23307540 — intervention group
Group type: EXPERIMENTAL
Intervention: Recommendations related to therapeutic drug and disease state monitoring
Number of subjects: 192
Study 23307540 — intervention group
Group type: EXPERIMENTAL
Intervention: Recommendations for patients with a greater number of drugs
Number of subjects: 192
Study 23307540 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall impact on health care use 90 days after discharge
Number of subjects: 192